Transfection of the c-myc oncogene into normal Epstein-Barr virus- harboring B cells results in new phenotypic and functional features resembling those of Burkitt lymphoma cells and normal centroblasts by unknown
Transfection of the c-myc Oncogene into Normal 
Epstein-Barr Virus-harboring B  Cells Results in New 
Phenotypic and Functional Features Resembling Those 
of Burkitt Lymphoma  Cells and Normal Centroblasts 
By Giovanna Cutrona, Massimo Ulivi, Franco  Fais, Silvio Roncella, and 
Manlio Ferrarini 
From the Istituto Nazionale per la Ricerca sul Cancro, IST, Servizio di Immunologia Clinica and 
Istituto di Oncologia Clinica e Sperimentale, Universith di Genova, Genoa 16132, Italy 
Summary 
Activated c-rnyc gene was introduced into the cells of three normal Epstein-Barr virus (EBV)-positive 
lymphoblastoid B cell lines (LCL).  The cells were monitored for the appearance of new pheno- 
typic and functional features compared with the control LCL cells transfected with plasmid that 
did not contain the c-myc gene. The LCL-expressing c-myc constitutively did not arrest growth 
in low serum concentration. However, the cell number in the cultures failed to increase because 
of substantial cell death. Death was due to apoptosis as demonstrated by flow cytometric analysis 
of propidium iodide-stained cells, by typical DNA laddering in gel electrophoresis, and by the 
inspection of Giemsa-stained cell smears. Apoptosis was also induced by exposing the transfected 
cells to antibodies directed to the immunoglobulin #  chain (a-#-ab) irrespective of the serum 
concentration in the culture. Exposure of the cells to CD40 ligand (CD40L) or CD40 mono- 
clonal antibody prevented cell apoptosis.  Upon transfection with c-myc, the LCL cells acquired 
a vacuolated morphology that was never observed in control cells. Moreover, the expression of 
CD10 and CD38 was upregulated, while that of CD39 and especially CD23 was downregulated. 
Unlike that observed in certain Burkitt lymphoma (BL) cell lines that share the same surface 
phenotype (CD10 +  CD38 +  CD23- CD39-),  the c-myc-transfected  cells expressed lymphocyte 
function-associated (LFA)  1, LFA-3,  and intercellular adhesion molecule 1 and grew in large 
clumps rather than single-cell layers. Expression of CD10 and CD38 was particularly evident 
on the cells undergoing apoptosis,  thus suggesting a correlation between the presence of these 
markers and the apoptotic process.  Cells placed in conditions favoring in vitro apoptosis dis- 
played downregulation of Bcl-2 protein. Bcl-2 expression was, however, upregulated when the 
cells were exposed to CD40L. These data indicate that the B cells expressing c-myc constitutively 
acquire some of the features of normal centroblasts and of BL cells, including the expression 
of CD10 and CD38,  and the propensity to undergo apoptosis,  which can be prevented by ex- 
posure to CD40L.  Therefore, these cells can serve as a model system to study both BL lym- 
phomagenesis as well as the process of B cell selection occurring in the germinal centers. 
I 
t is widely accepted that germinal centers (GCs) 1 repre- 
sent a major site for maturation of antibody affinity and 
the generation of B cell memory (1-4). Histologically, two 
different areas of the GC can be distinguished: the dark zone, 
which contains proliferating B lymphocytes, called centro- 
blasts, and the light zone, which is populated mainly by non- 
dividing B cells, called centrocytes (1). The centroblasts un- 
1  Abbreviations used in this  paper: a-#-ab, monoclonal  anti-/z antibody;  BL, 
Burkitt lymphoma;  eBL, endemic  BL; CD40L, CD40 ligand; GC, ger- 
minal center;  ICAM, intercellular  adhesion  molecule;  LCL, lymphoblastoid 
B cell line; PI, propidium iodide; RT, reverse transcriptase. 
dergo random hypermutation of the genes encoding the H 
and L chain V  regions of the Ig molecules and transform 
into resting centrocytes (1-4). Unless exposed to stimulatory 
signals, the centrocytes die by apoptosis (1-4), a form of pro- 
grammed suicide caused by the activation of endonucleases 
(5, 6). This process of hypermutation and subsequent selec- 
tion  contributes  to  the  diversification  of  the  antibody 
repertoire. 
Recently, it has become possible to obtain purified popu- 
lations of human GC B cells in vitro (7, 8). These cells have 
a characteristic surface phenotype (CD38+CD10+CD23 - 
CD39-) and die spontaneously in vitro by apoptosis.  Studies 
on the agents capable of preventing this in vitro apoptosis 
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selection that operates in the GC. Thus,  antibodies to sur- 
face Ig and the CD40 ligand  (CD40L)  are able to prevent 
apoptosis (7, 9,  10). In addition,  antibodies to CD38 or to 
CD21 inhibit apoptosis and prolong GC B cell survival (10, 
11). Some of these stimuli,  in combination with cytokines, 
may also  induce  proliferation  of GC  B  cells  and/or  their 
differentiation into Ig-secreting cells (7, 10-13). Despite this 
information,  the molecular mechanisms  that  induce apop- 
tosis or cause hypermutation  of the Ig V-region genes re- 
main to be elucidated.  Moreover, the function of the bcl-2 
protooncogene (14,  15), which has a key role in preventing 
apoptosis of other cell types (16,  17),  has been questioned 
in the case of GC B cells (9, 18-20).  Part of the difficulties 
in elucidating these issues is generated by technical problems 
related to both the handling of the GC B cells in vitro and 
the relatively low yield of cell purification procedures. In this 
respect,  the availability of continuous lines of cells sharing 
some or all of the features of the GC B cells would represent 
a substantial  improvement. 
A number of studies have shown that there are phenotypic 
and functional similarities between normal centroblasts and 
the malignant B cells of Burkitt lymphoma (BL) (8,  9, 21, 
22). Two types of BL can be distinguished  and are referred 
to as endemic BL (eBL) and sporadic BL (sBL) (23). While 
EBV infection is believed to play a major pathogenetic role 
in the eBL, the cells of sBL are generally EBV negative (23). 
Despite these differences, the cells  of the two types of BL 
share the same characteristic  features:  expression of a CD10 § 
CD38 + CD23- CD39-  surface phenotype,  absence or low 
expression of LFA-1, LFA-3, intercellular adhesion molecule 
(ICAM)-I and HLA class I antigens, presence of typical in- 
tracytoplasmic vacuoles, and a propensity to undergo apop- 
tosis (22-26). Some or all of these characteristics are retained 
by the ceils of the continuous lines derived from the EBV- 
negative BL (23).  In contrast,  the lines from EBV-positive 
BL have the tendency to shift their phenotype in vitro from 
that  of BL cells  (generally referred  to as the phenotype of 
group I BL cell lines) to that of normal lymphoblastoid EBV- 
positive cell lines,  which express abundant  CD23,  CD39, 
LFA-1, LFA-3, ICAM-1, and class I antigens, and low levels 
of CD10 and CD38 (phenotype of group III BL cell lines) 
(22,  27). 
Both eBL and sBL share similar cytogenetic and molec- 
ular abnormalities characterized primarily by the presence of 
a specific chromosomal translocation that results in the jux- 
taposition of the c-myc protooncogene with an Ig H  or L 
chain  gene (14,  23).  Although  there are differences in the 
topographic location of the chromosomal breakpoints of eBL 
and sBL (28), the translocation invariably causes a deregula- 
tion, which is frequently an upregulation,  of c-myc expres- 
sion (23, 29-33). This c-myc translocation is responsible for 
the acquisition of most of the malignant  features displayed 
by BL cells  (34,  35). 
Considering these observations, it is possible that consti- 
tutive expression of c-myc  may be responsible for some or 
all of the phenotypic and functional properties of BL cells, 
including the centroblast-like features and their propensity 
to undergo apoptosis. In an attempt to clarify this issue and 
with the aim of finding an in vitro system suitable for inves- 
tigating the control of GC B cells, we have transfected and 
expressed the c-myc gene in normal  EBV-positive lympho- 
blastoid B cell lines  (LCL). We show that c-myc activation 
is su~cient  to induce a change of phenotype from typical 
LCL to that characteristic  of centroblasts.  In addition,  the 
transfected cells become prone to death by apoptosis, from 
which  they can be rescued by exposure to CD40L.  Thus, 
besides indicating  a possible role for c-myc protooncogene 
in the physiology of GC cells, these data describe an in vitro 
model of potential value for investigating both the process 
of GC B cell selection and that  of BL lymphomagenesis. 
Materials  and Methods 
Plasmid Construction.  Plasmid pHEBo-E#-myc contains a frag- 
ment derived from the Manca BL cell line in which the transcrip- 
tion of the c-myc gene is controlled by the E/~ enhancer (36). The 
plasmid also contains the hygromicin resistance gene. This plasmid, 
kindly provided by Dr.  Carlo Croce (Jefferson Cancer Institute, 
Philadelphia, PA), was originally described by Lombardi et al. (34). 
The control plasmid, pHEBo-E/z, was generated by removing the 
XbaI-SalI fragment containing  the second and third c-myc exons 
from the original plasmid. 
Cell Lines and Cell Culture.  Two EBV-harboring LCL (Cot and 
Piz) were generated spontaneously from  two healthy EBV-sero- 
positive individuals. Per LCL was obtained from an HIV- and EBV- 
seropositive  patient. The LCL were obtained by culturing the PBMC 
in the presence of 50 ng/ml of cyclosporin A (Sandoz, Basel, Swit- 
zerland) as previously described (37). Small colonies of prolifer- 
ating cells began to appear in 20-50 d. These were collected and 
subsequently expanded in KPMI-1640 medium (Seromed Biochrom 
KG, Berlin, Germany) containing  10% FCS (Seromed Biochrom 
KG). Daudi was an EBV-positive malignant B cell line generated 
from a BL patient  (23). 
Cell Transfection.  Transfection was performed by electropora- 
tion (38). 5  x  106 cells were resuspended in 0.2 ml of cold PBS, 
and 10 #g ofplasmid DNA was subsequently added. The mixture 
was placed in an electroporation chamber and a high voltage (2.7-2.9 
kV) pulse was applied. Thereafter, the cells were placed in R.PMI 
with 10% FCS and cultured for 48 h before selection in the same 
medium  containing  300 U/ml  of hygromicin  B  (Calbiochem- 
Novabiochem Corp.,  San Diego,  CA). 
Growth Curves.  To determine their growth curves, the cells were 
resuspended at  a concentration  of 3  x  10S/ml in  RPMI-1640 
medium containing  10, 1, or 0.1% FCS, and placed in culture in 
24-well plates. Growth was measured by cell count at different in- 
tervals. Cell viability was assessed by trypan  blue exclusion. 
Cell Cycle Analysis.  Cell cycle analysis was carried out by flow 
cytometry according to the method described by Fried et al. (39). 
Briefly, 1.5  x  106 cells were centrifuged  at 200 g  and the cell 
pellets gently resuspended in 1.5 ml hypotonic fluorochrome solu- 
tion (propidium iodide [PI] 50 #g/ml) [Sigma Aldrich,  Milano, 
Italy], 0.1% sodium citrate, 0.1% Triton X-100) and placed in the 
dark overnight  at 4~  before flow cytometry analysis (Cytoron 
Absolute; Ortho Pharmaceuticals, Raritan, NJ). The data were sub- 
sequently analyzed by use of a computer program (Cell Cycle Pro; 
Ortho; ABS version 1.6C). 
Apoptosis Assays.  Cells to be tested for their capacity to un- 
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medium and plated in medium containing 10 or 0.1% FCS at con- 
centration of 3  x  10S/ml. In selected experiments, apoptosis was 
induced by exposing the cells (in RPMI-10%  FCS) to a mono- 
clonal anti-# antibody (a-/~-ab) coupled to polyacrylamide beads 
(Bio-Rad Laboratories, Richmond, CA) as previously described (8). 
Apoptosis was measured by three different methods. First, the cells 
were harvested at intervals and subsequently stained with an hypo- 
tonic PI fluorochrome solution and placed in the dark overnight 
at 4~  The amount of DNA fragmentation was measured by flow 
cytometry (40). Second, DNA laddering was measured according 
to the method of Facchinetti et al.  (41). Briefly,  10  s cells were 
resuspended in 5 ml of ice-cold lysing buffer (NaC1 150 mM, Tris 
50 mM [pH 7.6],  Triton X-100 1%,  10 mM EDTA, containing 
10 #g DNase-free RNase [Boehringer Manheim Biochemicals, In- 
dianapolis,  IN]); after 10 min on ice, the sample was centrifuged 
for 5 min at 2,000 rpm, and the supernatant containing DNA frag- 
ments was recovered. After phenol extraction and ethanol precipi- 
tation, the samples were resuspended in 50 #1 TE (Tris-EDTA). 
After 5 min at 60~  the fragments were loaded on a 1.5% agarose 
gel and run at 7.5 V/cm for 3 h. Third, Giemsa-stained  cytospin 
preparations were analyzed by light microscopy, and the percentage 
of cells with the morphological features  of apoptosis  were calcu- 
lated based  on a sample of 200 cells. 
Stimulation with CD40L or Anti-CD40 mA~  As a source of 
CD40L, the supernatant of mCD40L-CDS-cr  hybridoma, kindly 
provided by Dr. P. Lane (Basel Institute for Immunology, Basel, 
Switzerland) was used (42). This hybridoma produces a hybrid factor 
composed of one molecule of CD40L plus one of CD8-a. Cells 
were  resuspended  at  a  final  concentration  of 3  x  105/ml  in 
medium containing 10 or 0.1% FCS with or without CD40L su- 
pernatant at a final dilution of 1:20. This dilution was selected based 
on the results  of preliminary titration tests.  Cells were analyzed 
at several time intervals of up to 48 h for the presence of apoptosis. 
In selected experiments, apoptosis  was prevented by exposing the 
cells to the anti-CD40 mAb 626.1 (ascites used at the final dilution 
of 1:250), a generous gift of Dr. S. M. Fu (University of Virginia, 
Charlottesville, VA) (43). An unrelated mAb of the same isotype 
(anti-CD8;  Becton Dickinson & Co., Sunnyvale,  CA) was used 
as control. The optimal conditions of the stimuli used were selected 
after titration experiments. 
PCR Methodologies.  Total cellular  RNA was extracted using 
guanidinium isothiocyanate and CsC1 gradient procedures (44). For 
the reverse transcriptase (tLT) PCtL, the first strand of cDNA was 
synthesized from 2 #g of total RNA by use of 5 U of avian myelo- 
blastosis virus RT (Boehringer Mannheim), 100 pmol of oligo(dT)15 
(Boehringer Mannheim),  and 40 U  RNase inhibitor (Clontech, 
Palo Alto, CA) according to the manufacturers' instructions. 1/20 
of this first-strand cDNA reaction mixture was amplified with 2.5 
U Taq polymerase (Perkin Elmer Corp., Norwalk, CT) and 30 pmol 
of each of the following four synthetic primers in 50/~1 of Perkin 
Elmer buffer:  Myc  I/II  sense:  5'-gCACTggAACTTACAACA- 
CCC-3'; Myc I/II antisense:  5'-CgAggTCATAgTTCCTgTTgg-3'; 
Myc II/III sense: 5'-CATCATCCAggACTgTATgTgg-3';  and Myc 
II/III antisense:  5'-gTTgTTgCTgATCTgTCTCAgg-3'. 
After 27 amplification cycles (94~  for 1 min, 59~  for I min, 
and 72~  for 2 rain), 45/~1 of the PCR sample was run on a 1.4% 
agarose gel.  The PCR products were detected by ethidium bro- 
mide staining,  the gel was photographed with T55 film (Polaroid 
Corp., Cambridge, MA) and a densitometric analysis (LKB/Phar- 
macia Biotech, Brussels, Belgium) of the negative was performed. 
Western Blot Analysis.  Nuclear fractions were prepared by in- 
cubating the cells at a concentration of 107/ml in nuclear extrac- 
tion buffer (10 mM Tris-HC1, pH 7.9, 10 mM KC1, 1.5 mM MgC1, 
0.5 mM dithiothreitol, and 0.5 mM PMSF)  for 10 min at 0~ 
The cells were subsequently dounced in a homogenizer, and the 
resulting homogenates were layered over a cushion of 20% glycerol 
nuclear extraction buffer and then centrifuged at 250 g for 10 min. 
The pellets were solubilized by sonication in electrophoresis  sample 
buffer (50 mM  Tris-HC1,  pH  6.8,  2%  SDS,  4%  2-ME,  10% 
glycerol, and 0.01% bromophenol blue) and boiled for 3 min (44). 
106 nuclei of each sample were separated by discontinuous 8-16% 
SDS PAGE and electroblotted onto Hybond-C extra nitrocellulose 
membrane (Amersham International, Amersham, Bucks, UK). The 
membrane was  subsequently probed by use of an  anti-Myc hy- 
bridoma supernatant (9E10 done, kindly provided by Dr. R. Sitia, 
San Raffaele Institute, Milano,  Italy [45]) or a rabbit antiserum 
to histone 4 (kindly provided by Dr. M. Romani, IST, Genoa, Italy). 
To detect the Bcl-2 protein, total cell lysates rather than purified 
nuclei were used (10). Briefly, 106 cells were resuspended in elec- 
trophoresis sample buffer, sonicated, and run on a 14% acrylamide 
gel.  The  membrane  was  probed  with  a  Bd-2-specific  mAb 
(Dakopatts, Glostrup, Denmark). Second-step reactions were per- 
formed  by  a  peroxidase-linked  rabbit  anti-mouse  or  a  goat 
anti-rabbit antibody (Dakopatts). The antigens were visualized by 
chemoluminescence (ECL; Amersham International). 
Immunofluorescence.  The mAbs used were anti-CD19 (Leu 12), 
anti-human K and anti-~, Ig L chains from Becton Dickinson & 
Co.; anti-CD10 05) and anti-CD23 (B6) from Coulter Corp. (Hi- 
aleah, FL); anti-CD38 (IB4), kindly provided by Dr. F. Malavasi 
(University of Torino, Torino, Italy) (46); anti-CD39, kindly do- 
nated by Dr. M. Rowe (University of Birmingham, Birmingham, 
UK) (22); anti-LFA-1 (CD11a) and -LFA-3 (CD58), kindly provided 
by Dr. A. Poggi (IST); and ICAM-1 (CD54) from Serotec (Ox- 
ford, UK). All of these mAbs were used in indirect immunofluores- 
cence. The second FITC- or PE-conjugated antibodies to the ap- 
propriate murine Ig isotype were from Southern Biotechnology 
Associates (Birmingham, AL). Staining for cytoplasmic Bcl-2 was 
performed as previously described (10). Briefly, the cells were fixed 
in 1% paraformaldehyde/PBS solution, and the cell pellets were 
permeabilized for 3 min with 0.5 ml of 70% ethanol before in- 
direct immunofluorescence was performed with an anti-Bcl-2 mAb 
(Dakopatts).  All samples were analyzed by flow cytometry. 
Cell Separation.  Viable and apoptotic cells were physically sepa- 
rated by cell sorting (Epics-Elite flow cytometer; Coulter Corp.). 
The two populations were gated on the basis of forward and 90~ 
light scatter parameters  and,  after separation,  analyzed by flow 
cytometry and Western blotting for apoptosis and Bcl-2 expression. 
Results 
Establishment of c-myc-transfected LCL.  Vectors containing 
c-myc (pHEBo El~-myc) or control vectors (pHEBo E/~) were 
transfected into three different normal LCL (Cot,  Piz, and 
Per). The expression of the transfected c-myc gene was ana- 
lyzed by RT-PCR by use of two synthetic primer pairs. The 
myc I/II primer pair amplified a 224-bp fragment that spanned 
the first and second exons of c-myc and was derived from the 
endogenous LCL gene. The c-myc II/III primer pair produced 
a 633-bp fragment, which spanned the second and third exons 
of c-myc and was derived from both the endogenous and trans- 
fected genes (Fig. 1 A). With these primers, it was possible 
to detect an increase of the II/III exon fragment  over the 
I/II fragment in the c-myc-transfected  LCL as compared to 
the LCL transfected with  pHEBo E#  (Fig.  1 A). 
701  Cutrona et al. Figure  1.  Analysis  ofc-myc expression  by LCL. (tt) RT-PCR analysis 
ofc-myc mRNA expression  by I.CL transfected  with pHEBo  E# myc (Cor- 
myc, Per-myc,  Piz-myc)  or with pHEBo  E/~ (control  vector) (Cot-E#, Per- 
E#, Piz-El~). The last lane on the right (Neg Ct  0 contains the negative 
control represented  by the reaction  mixture without RNA. The maps of 
the transfected  c-myc  gene fragment as well as that of the c-myc  gene in 
germline  configuration  are reported  at the top of  the figure,  together  with 
the primers used for the RT-PCR. The ratios of the two amplification 
fragments and the percentage  of increase in the II/III fragment over  the 
I/II fragment in the c-myc-transfected compared  with control LCL are 
shown at the bottom of the figure. (B) Western  blot analysis of Myc ex- 
pression. The Western blot was run with purified  cell nuclei and probed 
with anti-Myc  mAb or an anti-H-4 polyclonal  rabbit antibody. In addi- 
tion to the nuclei  from the LCL transfected  with pHEBo  E# myc (Per-myc, 
Cor-myc, Piz-myc) or pHEBo  E/z (Per,, Cot, and Piz), those from Daudi 
cell line  and from normal PBMC were  also included  in the test as positive 
and negative controls, respectively. 
The expression of the Myc protein was analyzed  by Western 
blot (Fig. 1 B). Cor LCL transfected with c-myc (Cor-myc) 
expressed much higher quantities of Myc protein than the 
corresponding control (Fig. 1 B). Less marked, but neverthe- 
less substantial,  differences were noticed when Per-myc and 
Piz-myc LCL were compared with their respective controls 
(Fig.  1 B). 
To ensure that the transfection procedure did not select 
for  subclone(s)  with  special  properties,  the  ratio  of It:k- 
producing cells and the karyotypes of the two pairs were ana- 
lyzed. K and k L chain-expressing cells were detected in the 
same ratio in the c-myc-transfected and control LCL. Karyo- 
typic analysis failed to demonstrate chromosomal abnormal- 
ities in  the c-myc-transfected  and control LCL. 
Mode of  Growth of  c-myc-transfected LCL.  Next, the growth 
ability of each of the c-myc-transfected  LCL was compared 
with that of the corresponding control LCL in cultures con- 
taining three different FCS concentrations. Fig. 2 shows rep- 
resentative results obtained with Cor LCL. The c-myc-trans- 
fected LCL had a growth ability superior to the control LCL 
in the cultures supplemented with  10%  FCS,  whereas the 
growth curves of the c-myc-transfected  and control LCL were 
generally identical at 1% FCS concentrations (Fig. 2 A). The 
growth curves of the control LCL at 1 and 10% FCS were 
similar. At 0.1% FCS, the growth ability of the c-myc-trans- 
fected and control LCL slowed considerably and sometimes 
approached growth arrest. Occasionally, under these culture 
conditions, the growth of the c-myc-transfected  cells was mar- 
ginally superior to that  of the control LCL, as is the case 
in the experiment reported in  Fig.  2. 
A comparative analysis of the cell cycle of the c-myc-trans- 
fected and control LCL was carried out by flow cytometry. 
In the control LCL kept in 0.1% FCS, the proportion of cells 
in the S phase of the cycle decreased by 'x,50%  compared 
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Figure 2.  Growth curves of c-myc-transfected and control LCL. (.4) Growth curves of Cot LCL transfected with pHEBo E#-myc (Cor-myc) or with 
pHEBo E/~ (Cor-Elz) cultured in different FCS concentrations as indicated. (B) Cell cycle  analysis of c-myc-transfected  or control LCL kept in 10 or 
0.1% FCS for 48 h. Cells were PI stained and analyzed  by flow cytometry. The experiment reported (on Cor LCL) is representative  of the ones performed 
on Piz and Per I.CL. 
with the LCL cultured in 10% FCS (Fig. 2 B). In contrast, 
in the c-myc-transfected LCL there was no significant differ- 
ence between the proportion of cells in the S phase observed 
in 0.1 or 10% FCS (Fig. 2 B). Thus, unlike the control cells, 
which slowed their growth in low serum concentration, the 
c-myc-transfected cells continued to proliferate at 0.1% FCS. 
However, it is possible that the cultures failed to expand be- 
cause of the death of a portion of cells and not  simply be- 
cause of lack of proliferation. Analyses of cell viability in the 
different cultures confirmed that  this was the case.  While 
the viability of the control cells assessed by trypan blue ex- 
clusion remained high in all culture conditions (90-98% of 
viable cells), in the c-myc-transfected LCL, the cell viability 
at 72 h ofcuhure decreased from 95% in 10% FCS to 60-70% 
in low-FCS concentrations. 
Apoptosis ofc-myc-transfected Cells.  To explore the possi- 
bility that  the death of the c-myc-transfected  LCL cells in 
low serum concentration was caused by apoptosis, c-myc-trans- 
fected and control LCL were cultured in either  10 or 0.1% 
FCS,  harvested at intervals,  stained with PI,  and analzyed 
by flow cytometry. Fig. 3 A  reports the result of one repre- 
sentative experiment with Piz-myc LCL. The proportion of 
fragmented DNA in Piz-myc LCL was as high as 50% after 
24 h in the cultures  supplemented with 0.1%  FCS.  These 
values increased,  albeit slowly, over the next  72 h.  Under 
these culture conditions, the cell line was lost after ~,1 wk. 
In contrast,  apoptosis was very low when the c-myc-trans- 
fected cells were cultured in 10% FCS (Fig. 3 A). DNA lad- 
dering, a characteristic  feature of apoptotic cells, was observed 
by agarose gel electrophoresis in the c-myc-transfected cells 
cultured in 0.1% FCS but not in the same cells cultured with 
10%  FCS (Fig.  3 B) or in the control LCL (not  shown). 
Apoptosis was also measured by morphological inspection 
of Giemsa-stained cytospins. Cells with apoptotic nuclei were 
detected in the c-myc-transfected LCL kept at 0.1% FCS (Fig. 
3 C), but were virtually absent from those kept in 10% FCS 
(not  shown). 
Exposure to a-/z-ab of c-myc-transfected cells kept in 10% 
703  Cutrona  et al. Figure  3.  Apoptosis of c-myc-transfected  cells. (.4) Percentage of apoptosis determined on PI-stained cells by flow cytometry in Piz LCL transfected 
with pHEBo E/x (Piz) or with pHEBo E~t-myc  (Piz-myc).  The cells were cultured for different times with the indicated concentrations of FCS in the 
presence or absence of a-/~-ab. Apoptosis was measured by determining the percentage of fragmented DNA relative to the total DNA. The data are 
representative of those obtained with Cor and Per LCL. (B) Gel electrophoresis of total DNA from Cor and Per I_CL  transfected with pHEBo E#-myc 
to detect DNA laddefing diagnostic of apoptosis. The cells were cultured for 48 h with  the indicated concentrations of FCS. (C) Morphology of 
Per LCL transfected with pHEBo El~-m2/c.  The cells were cultured in 0.t%  FCS for 48 h before being stained with Giemsa. Apoptotic nuclei can 
be observed in the majority of the cells. 
FCS also caused apoptosis. In this case, the percentage of frag- 
mented DNA was as high as 80% after 72 h of culture (Fig. 
3 A). Serum deprivation and exposure to a-/~-ab had a syner- 
gistic effect on the inducement of apoptosis of the c-myc-trans- 
fected (but not control) cells. Thus, after 48 h, the percentage 
of apoptosis was >65%  and reached values >195% by 72 h. 
After this  time,  the c-myc-transfected LCL  were lost. 
CD40L Prevents Apoptosis of c-myc-transfected Cells.  The 
c-myc-transfected  cells were cultured in 0.1% FCS in the pres- 
ence or absence of CD40L, harvested at intervals, PI stained, 
and analyzed by flow-cytometry. Fig. 4 shows the results of 
one typical experiment  carried  out  on Cor-myc LCL.  The 
proportion of degraded DNA in the Cor-myc cells cultured 
in low serum concentration was as high as 55%  after 18 h. 
The presence of CD40L substantially lowered the percentage 
of degraded DNA, although the values observed were still 
higher than those detected in the cells cultured in 10% FCS. 
CD40L prevented apoptosis in the first 18 h of culture. After 
this  time,  the percentage of apoptosis observed in  the un- 
treated and CD40L-treated cultures became similar. R.eaddi- 
tion  of CD40L after  18  h  to the cultures  of the cells that 
had been already exposed to CD40L did not further delay 
the apoptotic process (not shown). Exposure to CD40L also 
o~ 
o 
60 
50 
40 
30 
20 
I'-IO.l~  FCS  ~'  C040L 
￿9  "\ 
n'-'-m  ~  o.  ,, Fcs 
/,0  0~0_......_...._...-.-..-.-.----..-0  IO1  FCS  / 
10  I  i  I  i  i 
0  12  24  36  48 
Hours 
Figure  4.  Inhibition of  apoptosis  by CD40L. Cor LCL transfected  with 
pHEBo EIx-myc  were cultured with  10 or 0.1% FCS in the presence or 
absence of the CD40L, as indicated. The cells were harvested at intervals 
and the percentage of apoptosis determined on PI-stained cells analyzed 
by flow cytometry. The results reported are representative of those ob- 
tained with  Piz and Per LCL. 
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a-/x-ab in 10% FCS, with kinetics identical to those observed 
for the transfected cells deprived of serum (not shown). Ex- 
posure to CD40 mAb caused an inhibition  of apoptosis of 
the c-myc-transfected cells similar to that observed with the 
CD40L  (not  shown). 
Phenotypic Changes of c-myc-transfected Cells.  The  above 
experiments  demonstrated  that  the  constitutive expression 
of c-myc induced the ability to undergo apoptosis that  was 
prevented by CD40L.  This propensity to undergo  sponta- 
neous apoptosis is a characteristic functional feature of both 
normal  centroblasts  and BL cells  (7,  9-11,  26).  Therefore, 
the c-myc-transfected cells were examined for the appearance 
of the phenotypic features shared by centroblasts and BL cells. 
This hypothesis was first analyzed by immunofluorescent tests 
with different mAbs on cells cultured in 10% FCS. The results 
of one representative experiment on the Cot LCL are shown 
in Fig.  5.  The control Cor LCL cells expressed high levels 
of CD39 and CD23, low levels of CD38,  and virtually no 
CD10 (Fig.  5 A). This is the phenotype of normal LCL (22, 
26). In the Cor-myc LCL, there was downregulation of CD39 
and especially of CD23  expression,  whereas the character- 
istic markers of BL cells and centroblasts, CD38 and CD10, 
were upregulated (Fig.  5 A). The constitutive expression of 
the c-myc oncogene also caused morphological changes.  As 
is apparent from the Giemsa-stained preparations (Fig.  5 B), 
the c-myc-transfected LCL were comprised of numerous vacuo- 
lated cells similar to the malignant  cells of BL (23). Vacuo- 
lated cells were consistently absent from the parental or con- 
trol  LCL (not  shown). 
The cells from the three c-myc-transfected LCL continued 
to grow in medium-  to large-sized clumps as normal  LCL 
do, rather  than  in single-cell carpets,  as is typical of group 
I BL cell lines.  Considering that  the c-myc-transfected  cells 
had undergone a significant change in phenotype toward that 
of BL cells (22, 23), this finding was somewhat unexpected. 
However, these data are consistent with the observation that 
the  c-myc-transfected  LCL  expressed  quantities  of surface 
ICAM-1,  LFA-1,  or LFA-3 no different from those of the 
control or parental I.CL (24) as assessed by immunofluores- 
cence staining and flow cytometry analysis (data not shown). 
This is different from that reported for group I BL cells that 
downregulate the expression  of these adhesion molecules (24). 
Increased Expression of CD38 and CDIO and Downregulation 
of Bcl-2 in c-myc-transfected Cells Undergoing Apoptasis. Im- 
munofluorescence tests were carried out on c-myc-transfected 
cells cultured at 0.1% FCS for 48 h to ascertain  whether there 
was a difference in CD10 and/or CD38 expression I by apop- 
totic cells compared with nonapoptotic cells. Two groups of 
cells could be distinguished by forward and side light scatter 
in Per-myc LCL cultured  in 0.1%  FCS (Fig.  6 A,  Gates 1 
and 2). Separation of each of the two groups by cell sorting 
followed by PI staining  of the cells  and reanalysis by flow 
cytometry disclosed that the apoptotic cells were concentrated 
within  the cells in gate 1, whereas the cells in gate 2 were 
virtually devoid of apoptotic cells (Fig. 6 A). Moreover, the 
cells in gate 1 had low to nonexistent  Bcl-2 protein levels, 
whereas Bcl-2 was readily demonstrable by Western blot in 
the cells in gate 2 (Fig.  6 C). The cells in gate 1 were charac- 
terized by the expression of higher levels of CD10 and CD38 
and lower levels of CD39 and CD23 compared with the cells 
in gate 2 (Fig. 6 B). The figure also shows the results of staining 
for these markers of the control Per LCL. These cells were 
more brightly stained for CD23 and CD39 than the nonapop- 
totic cells in gate 2. Conversely, the expression of CD10 and 
CD38 was lower. Therefore, it appears that constitutive c-myc 
expression  causes  a shift  in  phenotype  that  becomes more 
apparent after the cells are induced into apoptosis.  These apop- 
totic cells phenotypically resemble both the BL cells and the 
centroblasts. 
Figure 5.  Phenotypic  changes induced by the constitutive expression of c-myc. (.4) Surface  phenotype of Cor I.CL cells transfected with pHEBo 
E#-myc (black  areas)  or pHEBo  E/~ (white  areas).  The cells  were stained with the indicated mAb and analyzed  by flow  cytometry.  (CTR) Control staining 
with an irrelevant mAb. (B) Morphology  of  Cor LCL transfected  with pHEBo  E#-myc.  Numerous  vacuoles  are present in the cytoplasm  of the transfected 
cells. The results reported are representative of those obtained with Piz and Per LCL. 
705  Cutrona  et al. Figure  6.  Increased  expression  of 
CD10 and CD38 and downregula- 
tion of Bcl-2  after apoptosis. (A) Per 
LCL cells transfected with pHEBo 
E#-m  F  were cultured with 0.1% 
FCS for 48 h and analyzed by flow 
cytometry. Two populations of cells 
were detected by foward (vertical 
axis) and side (horizontal axis) light 
scatter and subsequently separated 
by appropriate gating. After sepa- 
rations, the cells in gates 1 or 2 were 
PI  stained and  analyzed by flow 
cytometry to detect degraded  DNA, 
which  is diagnostic of apoptosis. 
Apoptosis was  almost exchsively 
observed  only in the cells in gate 1. 
(B) Expression of surface markers 
by Per-rayc  LCL cells separated ac- 
cording to their capacity  to undergo 
apoptosis (as depicted in A). The 
cells were stained  with the indicated 
mAbs and analyzed  by flow cytom- 
etry. Apoptotic calls (Gate I, black 
areas) express more CD10 and C38 
than  nonapoptotic  calls (Gate  2, 
white areas). These latter cells have 
more abundant CD23 and CD39. 
(Dotted lines) Flow cytometry profile 
observed with the same reagents in 
the parental Per LCL cells. (C) Western blot analysis of Bcl-2 expression by Per-rayc  LCL calls. The cells were cultured in 0.1% FCS for 48 h, separated 
as in A, and analyzed by Western blot.  The results shown are representative of those obtained with Cor and Piz LCL. 
Bcl-2 Expression  by c-myc-transfected  Cells.  In these experi- 
ments, we investigated whether exposure to CD40L of the 
c-myc-transfected  cells cultured in low serum concentration 
results in upregulation of Bcl-2 expression. Fig.  7 reports the 
results of one representative experiment carried out  on Piz- 
myc LCL. In this experiment, the cells were cultured in 0.1% 
FCS in the presence or absence of CD40L,  harvested at in- 
tervals, and studied for Bcl-2 expression by immunofluores- 
cence. This technique was selected over the Western blot used 
above as it proved more reliable in measuring variations in 
the Bcl-2 expression as assessed in the course of preliminary 
experiments.  With this fluorescent method,  which requires 
cell permeabilization,  it was not possible to distinguish  the 
apoptotic from the nonapoptotic  cells by forward  and  side 
light  scatter  as in  the  experiments  shown  in  Fig.  6.  After 
1 h of culture in low FCS concentration,  virtually no differ- 
ence in the expression of Bcl-2 was noted between the cells 
exposed  to  CD40L  and  those  that  were  not  exposed  (Fig. 
7).  Bcl-2 expression  in  the cells cultured  in  the  absence of 
CD40L was decreased after 3 h, whereas this decrease of Bcl-2 
expression was not detected in the cells exposed to CD4OL. 
In fact, in these cells there was an increase, albeit a marginal 
one, of Bcl-2 expression compared with the values observed 
after 1 h of culture under the same conditions (Fig.  7). After 
18 h  of culture,  the majority of the cells exposed to CD40L 
expressed Bcl-2, whereas in the cultures that did not contain 
CD40L, two group of cells could be distinguished.  One was 
virtually negative for Bcl-2 expression,  while the other had 
a  Bcl-2  fluorescent  intensity  almost  comparable  to  that  of 
the cells exposed to CD40L.  After 48 h,  the vast majority 
of cells cultured in the absence of CD40L expressed very little 
or no Bcl-2 (Fig.  7). The cells exposed to CD40L displayed 
a higher level of Bcl-2 expression.  However,  the amount of 
Bcl-2 detected  was clearly lower than  that  of the cells cul- 
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Figure  7.  Induction of Bcl-2 expression by exposure to CD40L. Piz 
LCL cells transfected  with pHEBo E#-myc were cultured for the indicated 
times in 0.1% FCS in the presence or absence of the CD40L. The cells 
were permeabilized, stained for Bcl-2, and analyzed by flow cytometry. 
(Black areas) Flow cytometry profile of the cells cultured with CD40L; 
(white areas) flow cytometry profile of the cells cultured without CD40L. 
(Dotted lines) Bcl-2 expression  by Piz-myc  cells cultured in 10% FCS. The 
results reported are representative  of those obtained with Cor and Per LCL. 
706  B Cell Modifications Induced by c-m  F  Transfection tured for 18 h. Thus, prolonged culture, even in the presence 
of CD40L, resulted in a Bd-2 downregulation consistent with 
the data on apoptosis shown in Fig. 4.  It should be noted 
that the immunofluorescent method used generally results 
in a slight overestimation of the Bcl-2-positive cells in the 
suspension cultured for prolonged times, as the permeabili- 
zation method selectively eliminated dead cells. Because of 
this difficulty and poor cell recovery, determination of Bcl-2 
at 72 h could not be performed. These findings are in line 
with those obtained with the Western blot analysis reported 
in Fig. 6 and corroborate the presence of cells that have low 
or absent Bcl-2 expression and are apoptosis prone, as well 
as cells that still express some Bcl-2 that are apoptosis resis- 
tant,  at least over a short period of time. 
Discussion 
This study demonstrates that the constitutive expression 
of the c-myc oncogene induces a number of phenotypic and 
functional changes in the cells of normal EBV-positive LCL. 
These changes include (a) the expression of CD10 and CD38; 
(b) the downregulation of CD23 and CD39; (c) the acquisi- 
tion of a vacuolated morphology; and (d) the capacity to un- 
dergo apoptosis.  Exposure to CD40L or CD40 mAb pre- 
vents  apoptosis  from  occurring.  Because  of these  newly 
acquired features, the cells transfected with c-myc resemble 
the malignant cells of BL and normal centroblasts. 
Apoptosis of the c-myc-transfected cells was observed in 
low serum concentration, a condition that caused an apparent 
growth arrest similar to that observed in the control LCL 
(Fig. 2). However, in the c-myc-transfected LCL, the number 
of cells in the S phase of the cell cycle did not decrease as 
in the control LCL, but remained as high as in the LCL kept 
in  10%  FCS.  The  cells  underwent  apoptosis  instead  of 
progressing normally into the cell cycle. Thus, c-myc expres- 
sion, combined with a block to proliferation, appears  to be 
a potent inducer of apoptosis in B cells, similar to that de- 
scribed in cells of other tissue origin (47-49).  This mecha- 
nism is likely to represent a general safety device for aborting 
cell division initiated by c-myc activation when some cata- 
strophic event, like c-myc mutation,  occurs. In the case of 
GC B cells, it may also have a special function in the selec- 
tion of cells producing the highest affinity antibodies to the 
stimulating antigen(s). 
Apoptosis of c-myc-transfected cells was prevented by ex- 
posure to CD40L (or CD40 mAb), similar to that observed 
with normal centroblasts (9-10). Moreover, anti-CD38 mAb 
that normally prevents apoptosis of centroblasts (10) simi- 
larly inhibits apoptosis of the c-myc-transfected LCL (data 
not shown). Thus, the c-myc-transfected LCL seem to retain 
the capacity to respond to some (or even all) of the signals 
that regulate GC B cell selection in vivo. The inhibition of 
apoptosis of c-myc-transfected LCL with CD40L (or CD40 
mAb) was short-lived (Fig. 4). This is similar to what is ob- 
served with normal centroblasts, which can be, however, rein- 
duced into the cell cycle by exposure to IL4 (10). This finding 
perhaps suggests that signaling via CD40 prolongs cell sur- 
vival in preparation for other signals for proliferation. Un- 
fortunately, despite the use of a battery of cytokines, we have 
so far been unable to reinduce cell proliferation of c-myc-trans- 
fected LCL after apoptosis  has been inhibited by CD40L. 
Exposure of the c-myc-transfected cells to CD40L in vitro 
was followed by upregulation of Bcl-2 expression (Fig.  7). 
In addition, Bcl-2 was normally present in the c-myc-trans- 
fected cells kept at high FCS concentration (Fig.  7), while 
it decreased substantially in those kept at low FCS concen- 
tration and was virtually absent from the cells purified after 
apoptosis had been induced (Fig. 6). Finally, the short-lived 
inhibition of apoptosis caused by exposure to CD40L cor- 
related closely with the cell capacity to express Bd-2 (see Fig. 
7).  Together,  these  data  indicate  a  key role  of Bcl-2  in 
preventing apoptosis of c-myc-transfected cells. Therefore, if 
the constitutive expression of c-myc predisposes the cell to 
either proliferation or apoptosis, then the bd-2 protooncogene 
system appears to dictate the outcome of the options imposed 
on the cell (50, 51). This notion is consistent with the data 
obtained on cells ofnonlymphoid origin (16, 17, 52, 53) and 
would  provide  a  conceptual  framework  for  the  various 
processes  of cell selection that  occur within  the immune 
system. The stimuli received by T or B lymphocytes through 
their surface antigen receptors are known to upregulate c-myc 
expression (32, 54-56). These stimuli would, therefore, pre- 
dispose the cell toward either proliferation or apoptosis, the 
final decision between the two options eventually being dic- 
tated by signals that govern bcl-2 protooncogene expression. 
Evidence, albeit indirect, in favor of a mechanism of this type 
exists in the case of T  cell selection in the thymus and the 
inhibition of excessive T  cell expansion during viral infec- 
tions (54, 55, 57, 58). In connection with this, it is of note 
that we have recently found that a large fraction (up to 60%) 
of freshly isolated GC B ceils are in the S phase of the cell 
cycle and express high levels ofMyc (Zupo, S., personal com- 
munication), thus indicating that c-myc upregulation may 
play a role in the selection of GC B cells. 
Apoptosis of c-myc-transfected calls deprived of serum or 
exposed to a-#-ab occurred over a relatively expanded period 
of time,  and the LCL experienced increasing difficulty in 
growing before being definitively lost. These findings could 
indicate that the decision between apoptosis and progression 
into the cell cycle may be governed by certain stochastic factors. 
In addition, they may suggest the presence of certain as yet 
unidentified stimuli in the cultures capable of upregulating 
bcl-2 expression in a proportion of cells. Such a hypothesis 
is supported by the finding that certain cells expressed Bcl-2 
even under culture conditions that favor apoptosis (Fig.  6). 
Apoptosis of c-myc-transfected cells was induced by cul- 
turing the cells in low FCS concentration or by culturing 
in the presence of a-#-ab irrespective of the FCS concentra- 
tions in the culture. The synergistic effect of the exposure 
to a-#-ab and serum deprivation may suggest that the two 
signals fonow somewhat different pathways in inducing cell 
apoptosis.  Although the fine mechanisms involved are still 
largely unknown, some hypotheses amenable to further ex- 
perimental testing can be presented. For example, in low FCS 
concentrations, the cells were likely to lack those stimula- 
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pression in order to counterbalance the effect of Myc overex- 
pression.  In the case of a-/~-ab-induced apoptosis,  ligation 
of surface IgM may have caused an increased expression of 
endogenous c-myc, thus altering the normal balance between 
Myc and Bcl-2. This hypothesis would offer a plausible,  al- 
beit incomplete, explanation as to why exposure to a-#-ab 
causes apoptosis in certain B cells while preventing apoptosis 
and even inducing proliferation in others (7, 59). Studies along 
these lines are in progress. 
The constitutive expression ofc-myc caused changes in the 
cell phenotype consisting of downregulation of CD23 and 
CD39 and upregulation of CD10 and CD38. These findings 
demonstrate that of the various cytogenetic alterations of BL 
cells (23, 60), those involving the c-myc oncogene are respon- 
sible for the acquisition of a new cell phenotype. It is of in- 
terest in this connection that CD10 and CD38 expression 
was particularly evident in those cells that had been induced 
to undergo apoptosis in vitro, a finding that might suggest 
a role for the two markers in the apoptosis itself and/or its 
prevention. A number of observations would argue for this 
notion. First, both CD10 and CD38 are expressed by group 
I BL cell lines, which are apoptosis prone, and not by group 
III BL cell lines, which are resistant to apoptosis (26). Second, 
certain agonistic anti-CD38 mAbs prevent apoptosis of normal 
centroblasts  (10) and c-myc-transfected LCL (data not shown). 
Third, malignant myeloid cells also express CD10 and CD38 
when exposed to stimuli in vitro that render them prone to 
apoptosis (61). Fourth, normal EBV-positive LCL cells, when 
infected by HIV in vitro, undergo apoptosis readily and con- 
comitantly express surface CD10 (62). If c-myc controls some 
of the cells' phenotypic features as well as their propensity 
to undergo apoptosis, it is then possible that the differences 
in phenotype and apoptotic capacity of group I BL cells, group 
III BL cells, and c-myc-transfected cells may in part depend 
on the different levels of c-myc expressed. Studies along this 
line are currently in progress. 
Previously, it was reported that transfection of c-myc into 
normal EBV-positive LCL induced the acquisition of malig- 
nant properties such as the capacity to form colonies in semi- 
solid agar or grow in nude mice (34), but did not usually 
cause phenotypic changes except for the possible dowuregu- 
lation of surface LFA-1 expression (63).  Although we have 
been able to confirm that the c-myc-transfected cells acquired 
malignant properties (data not shown), we also have consis- 
tently observed the phenotypic changes described above, which 
do not include LFA-1 downregulation. These discrepancies 
may, in part, be due to the different plasmids used. Moreover, 
since both apoptosis and upregulation of CD10 and CD38 
are best observed when a block to cell proliferation is im- 
posed, the culture system used for cell selection and testing 
(particularly the FCS concentrations), may have influenced 
the outcome of the experimental observations. 
The c-myc-transfected cells retained the capacity of normal 
LCL to express high-density surface adhesion molecules and 
grew in large cellular clumps. Moreover, the c-myc-transfected 
cells expressed the full set of EBV latent antigens. This is 
similar to the results observed for normal LCL and is different 
from those  occurring in  most  BL cells  that  express  only 
Epstein-Barr nuclear antigen 1 (EBNA-1) antigens (22). The 
EBV lytic antigens were, however, consistently absent, thus 
ruling out that the death ofc-myc-transfected celts was caused 
by reactivation of a lytic infection (Fais, F., G. Cutrona, S. 
Roncella, and M. Ferrarini, manuscript in preparation). Al- 
though the discussion of these issues goes beyond the scope 
of this study, a few points deserve special comment. First, 
these findings demonstrate that constitutive expression of c-myc 
does not result per se in the downregulation of the expres- 
sion of either EBV latent antigens or of surface adhesion mol- 
ecules. Therefore, it appears that in eBL cells, which express 
only EBNA-1 and have low surface adhesion molecules (23), 
these phenotypic features are acquired independently of the 
c-myc translocation during lymphomagenesis. The observa- 
tions made on the malignant BL cells obtained from certain 
AIDS patients and on group III BL cell lines,  all of which 
have a translocated c-myc and express the full set of EBV la- 
tent antigens and surface adhesion molecules, would argue 
for this notion (64-66).  Second, it is widely accepted that 
in  cells  latently infected by EBV, EBNA-2  promotes  the 
progression of the cells into the cell cycle and induces the 
expression of CD23  and CD39,  whereas latent membrane 
protein-1 (LMP-1) upregulates bcl-2 protooncogene expres- 
sion, thus preventing apoptosis (22, 26). These findings seem 
to indicate that these mechanisms, which promote cell prolifer- 
ation and survival, may sometimes be overridden by the con- 
stitutive expression of c-myc. It is possible  that the mode of 
expression of latent viral genes plays a crucial role in deter- 
mining the cellular phenotype and the differences observed 
between group I BL cells, group III BL cells, and c-myc-trans- 
fected LCL. However, the mechanisms that regulate both viral 
gene expression and the mutual controls possibly existing 
between the c-myc oncogene and EBV gene expression re- 
main to be elucidated. The c-myc-transfected LCL reported 
here may represent a useful investigative tool in this field. 
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